OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Huntington’s Disease Clinical Trials Corner: August 2023
Carlos Estevez‐Fraga, Sarah J. Tabrizi, Edward J. Wild
Journal of Huntington s Disease (2023) Vol. 12, Iss. 2, pp. 169-185
Open Access | Times Cited: 27
Carlos Estevez‐Fraga, Sarah J. Tabrizi, Edward J. Wild
Journal of Huntington s Disease (2023) Vol. 12, Iss. 2, pp. 169-185
Open Access | Times Cited: 27
Showing 1-25 of 27 citing articles:
Advances in MicroRNA Therapeutics: from Preclinical to Clinical Studies
Simona Brillante, Mariagrazia Volpe, Alessia Indrieri
Human Gene Therapy (2024) Vol. 35, Iss. 17-18, pp. 628-648
Closed Access | Times Cited: 18
Simona Brillante, Mariagrazia Volpe, Alessia Indrieri
Human Gene Therapy (2024) Vol. 35, Iss. 17-18, pp. 628-648
Closed Access | Times Cited: 18
Huntington’s Disease Clinical Trials Corner: March 2024
Carlos Estevez‐Fraga, Sarah J. Tabrizi, Edward J. Wild
Journal of Huntington s Disease (2024) Vol. 13, Iss. 1, pp. 1-14
Open Access | Times Cited: 15
Carlos Estevez‐Fraga, Sarah J. Tabrizi, Edward J. Wild
Journal of Huntington s Disease (2024) Vol. 13, Iss. 1, pp. 1-14
Open Access | Times Cited: 15
Dietary fasting and time-restricted eating in Huntington’s disease: therapeutic potential and underlying mechanisms
Russell G. Wells, Lee Neilson, Andrew W. McHill, et al.
Translational Neurodegeneration (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 11
Russell G. Wells, Lee Neilson, Andrew W. McHill, et al.
Translational Neurodegeneration (2024) Vol. 13, Iss. 1
Open Access | Times Cited: 11
Huntington’s Disease: Latest Frontiers in Therapeutics
Joseph Saade, Tiago Mestre
Current Neurology and Neuroscience Reports (2024) Vol. 24, Iss. 8, pp. 255-264
Closed Access | Times Cited: 11
Joseph Saade, Tiago Mestre
Current Neurology and Neuroscience Reports (2024) Vol. 24, Iss. 8, pp. 255-264
Closed Access | Times Cited: 11
Application of antisense oligonucleotide drugs in amyotrophic lateral sclerosis and Huntington’s disease
Kaili Ou, Qingqing Jia, Dandan Li, et al.
Translational Neurodegeneration (2025) Vol. 14, Iss. 1
Open Access | Times Cited: 1
Kaili Ou, Qingqing Jia, Dandan Li, et al.
Translational Neurodegeneration (2025) Vol. 14, Iss. 1
Open Access | Times Cited: 1
A randomized clinical trial to evaluate the efficacy of cognitive rehabilitation and music therapy in mild cognitive impairment in Huntington’s disease
Andrea Moreu-Valls, Arnau Puig‐Davi, Saül Martínez‐Horta, et al.
Journal of Neurology (2025) Vol. 272, Iss. 3
Closed Access | Times Cited: 1
Andrea Moreu-Valls, Arnau Puig‐Davi, Saül Martínez‐Horta, et al.
Journal of Neurology (2025) Vol. 272, Iss. 3
Closed Access | Times Cited: 1
Immune responses to central nervous system directed adeno-associated virus gene therapy: Does direct CNS delivery make a difference?
Ashley L. Harkins, Prajakta P Ambegaokar, Allison M. Keeler
Neurotherapeutics (2024) Vol. 21, Iss. 4, pp. e00435-e00435
Open Access | Times Cited: 7
Ashley L. Harkins, Prajakta P Ambegaokar, Allison M. Keeler
Neurotherapeutics (2024) Vol. 21, Iss. 4, pp. e00435-e00435
Open Access | Times Cited: 7
Polyglutamine disease proteins: Commonalities and differences in interaction profiles and pathological effects
Megan Bonsor, Orchid Ammar, Sigrid Schnoegl, et al.
PROTEOMICS (2024) Vol. 24, Iss. 12-13
Open Access | Times Cited: 6
Megan Bonsor, Orchid Ammar, Sigrid Schnoegl, et al.
PROTEOMICS (2024) Vol. 24, Iss. 12-13
Open Access | Times Cited: 6
Advances in Gene and Cellular Therapeutic Approaches for Huntington’s Disease
Xuejiao Piao, Dan Li, Hui Liu, et al.
Protein & Cell (2024)
Open Access | Times Cited: 5
Xuejiao Piao, Dan Li, Hui Liu, et al.
Protein & Cell (2024)
Open Access | Times Cited: 5
Oligonucleotide-Based Therapeutics for Neurodegenerative Disorders: Focus on Antisense Oligonucleotides
Heba M. Mansour, Aiman S. El‐Khatib
European Journal of Pharmacology (2025), pp. 177529-177529
Closed Access
Heba M. Mansour, Aiman S. El‐Khatib
European Journal of Pharmacology (2025), pp. 177529-177529
Closed Access
Huntington's disease clinical trials update: March 2025
Mena Farag, Sarah J. Tabrizi, Edward J. Wild
Journal of Huntington s Disease (2025)
Closed Access
Mena Farag, Sarah J. Tabrizi, Edward J. Wild
Journal of Huntington s Disease (2025)
Closed Access
Cas9 nickase-mediated contraction of CAG/CTG repeats at multiple disease loci
Alvaro Murillo, Melanie Alpaugh, Meghan Larin, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 3
Alvaro Murillo, Melanie Alpaugh, Meghan Larin, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 3
Huntington’s Disease Clinical Trials Update: September 2024
Mena Farag, Sarah J. Tabrizi, Edward J. Wild
Journal of Huntington s Disease (2024) Vol. 13, Iss. 4, pp. 409-418
Closed Access | Times Cited: 3
Mena Farag, Sarah J. Tabrizi, Edward J. Wild
Journal of Huntington s Disease (2024) Vol. 13, Iss. 4, pp. 409-418
Closed Access | Times Cited: 3
Melatonin ameliorates ischemic brain injury in experimental stroke by regulation of miR-221 and ATG7 Axis
Xu Liu, Yue Zhang, Yumei Ma, et al.
Biochemical and Biophysical Research Communications (2025), pp. 151706-151706
Closed Access
Xu Liu, Yue Zhang, Yumei Ma, et al.
Biochemical and Biophysical Research Communications (2025), pp. 151706-151706
Closed Access
Preventing acute neurotoxicity of CNS therapeutic oligonucleotides with the addition of Ca2+ and Mg2+ in the formulation
Rachael Miller, Joseph Paquette, Alexandra Barker, et al.
Molecular Therapy — Nucleic Acids (2024) Vol. 35, Iss. 4, pp. 102359-102359
Open Access | Times Cited: 2
Rachael Miller, Joseph Paquette, Alexandra Barker, et al.
Molecular Therapy — Nucleic Acids (2024) Vol. 35, Iss. 4, pp. 102359-102359
Open Access | Times Cited: 2
Assessment of Perivascular Space Morphometry Across the White Matter in Huntington’s Disease Using MRI
Annabelle Coleman, Mackenzie Langan, Gaurav Verma, et al.
Journal of Huntington s Disease (2024) Vol. 13, Iss. 1, pp. 91-101
Open Access | Times Cited: 2
Annabelle Coleman, Mackenzie Langan, Gaurav Verma, et al.
Journal of Huntington s Disease (2024) Vol. 13, Iss. 1, pp. 91-101
Open Access | Times Cited: 2
Brain–Periphery Interactions in Huntington’s Disease: Mediators and Lifestyle Interventions
Johannes Burtscher, Barbara Strasser, Giuseppe Pepe, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 9, pp. 4696-4696
Open Access | Times Cited: 2
Johannes Burtscher, Barbara Strasser, Giuseppe Pepe, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 9, pp. 4696-4696
Open Access | Times Cited: 2
Preventing acute neurotoxicity of CNS therapeutic oligonucleotides with the addition of Ca2+ and Mg2+ in the formulation
Rachael Miller, Joseph Paquette, Alexandra Barker, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Rachael Miller, Joseph Paquette, Alexandra Barker, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Profiling deutetrabenazine extended-release tablets for tardive dyskinesia and chorea associated with Huntington’s disease
Priyanka Moondra, Joohi Jimenez‐Shahed
Expert Review of Neurotherapeutics (2024) Vol. 24, Iss. 9, pp. 849-863
Closed Access | Times Cited: 1
Priyanka Moondra, Joohi Jimenez‐Shahed
Expert Review of Neurotherapeutics (2024) Vol. 24, Iss. 9, pp. 849-863
Closed Access | Times Cited: 1
Huntingtin lowering impairs the maturation and synchronized synaptic activity of human cortical neuronal networks derived from induced pluripotent stem cells
Mathilde Louçã, Donya El Akrouti, Aude Lemesle, et al.
Neurobiology of Disease (2024) Vol. 200, pp. 106630-106630
Open Access | Times Cited: 1
Mathilde Louçã, Donya El Akrouti, Aude Lemesle, et al.
Neurobiology of Disease (2024) Vol. 200, pp. 106630-106630
Open Access | Times Cited: 1
PET Ligands for Imaging Mutant Huntingtin Aggregates: A Case Study in Non‐For‐Profit Scientific Management
Catherine G. Fitzgerald Dickmann, Selena Milicevic Sephton, Roger A. Barker, et al.
ChemBioChem (2024) Vol. 25, Iss. 11
Open Access
Catherine G. Fitzgerald Dickmann, Selena Milicevic Sephton, Roger A. Barker, et al.
ChemBioChem (2024) Vol. 25, Iss. 11
Open Access
Review of the Use of Antisense Oligonucleotides as Therapy for Huntington's Disease
Ariel Solis-Chiriboga, Alberto Bustillos
Salud Ciencia y Tecnología - Serie de Conferencias (2024) Vol. 3, pp. 923-923
Open Access
Ariel Solis-Chiriboga, Alberto Bustillos
Salud Ciencia y Tecnología - Serie de Conferencias (2024) Vol. 3, pp. 923-923
Open Access
Review of the Use of Antisense Oligonucleotides as Therapy for Huntington's Disease
Ariel Solis-Chiriboga, Alberto Bustillos
Salud Ciencia y Tecnología - Serie de Conferencias (2024) Vol. 3, pp. 795-795
Open Access
Ariel Solis-Chiriboga, Alberto Bustillos
Salud Ciencia y Tecnología - Serie de Conferencias (2024) Vol. 3, pp. 795-795
Open Access
Epidemiology of Huntington's Disease in Latin America: A Systematic Review and Meta‐Analysis
Alex Medina, Tamara Pringsheim, Sylvia Gautreau, et al.
Movement Disorders (2024) Vol. 39, Iss. 11, pp. 1907-1921
Closed Access
Alex Medina, Tamara Pringsheim, Sylvia Gautreau, et al.
Movement Disorders (2024) Vol. 39, Iss. 11, pp. 1907-1921
Closed Access
